Ligand Pharmaceuticals Inc.

516 articles with Ligand Pharmaceuticals Inc.

• Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

  2/22/2023

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2022, and provided an operating forecast and business updates.

• Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

  2/17/2023

  Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. has received accelerated approval from the U.S. Food and Drug Administration for FILSPARI™ to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.

• Ligand to Report Fourth Quarter Financial Results on February 22

  2/6/2023

  Ligand Pharmaceuticals Incorporated will report fourth quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, February 22, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

• Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

  1/6/2023

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum (molluscum).

• Ligand Provides Highlights from its Investor and Analyst Day Event

  12/13/2022

  Ligand Pharmaceuticals Incorporated announced that at ’s Investor and Analyst Day event its executive management provided an overview of Ligand’s corporate structure and business following the successful spin-off of its OmniAb antibody discovery business, reviewed Ligand’s recent progress and near-term partner milestones and provided an outlook for financial growth.

• Ligand Pharmaceuticals Names Director Todd C. Davis as CEO

  12/5/2022

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that John Higgins has retired as Chief Executive Officer, effective as of today, and that the company’s board of directors has named Todd C. Davis as Chief Executive Officer.

• Ligand to Hold Investor and Analyst Day on December 13

  11/16/2022

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time (8:00 a.m. to 9:30 a.m. Pacific time).

• Ligand Reports Third Quarter 2022 Financial Results

  11/7/2022

  Ligand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates.

• 

  FDA Action Alert: Seagen and Provention PDUFA Dates on the Horizon

  11/7/2022

  The FDA is gearing up for deadlines and PDUFA dates in mid-November with Seagen, Provention, Clarus and Tolmar, and Ligand and Travere.

• Ligand Distribution of OmniAb Complete and Business Combination Closed

  11/1/2022

  Ligand Pharmaceuticals Incorporated announced the completion of its expected tax-free distribution of 100% of Ligand’s interest in its subsidiary OmniAb on a pro rata basis to Ligand shareholders of record as of October 26, 2022.

• OmniAb Announces Completion of Spin-Off and Business Combination

  11/1/2022

  OmniAb, Inc. announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated and the subsequent business combination with Avista Public Acquisition Corp. II, resulting in OmniAb becoming an independent publicly traded company.

• Ligand Announces Completion of OmniAb Spin-Off

  11/1/2022

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the company has completed the expected tax-free spin-off of its OmniAb antibody discovery business which has become OmniAb, Inc., an independent publicly traded company.

• Ligand to Report Third Quarter Financial Results on November 7

  10/26/2022

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report third quarter 2022 financial results after the close of the U.S. financial markets on Monday, November 7, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

• Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  10/26/2022

  Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI ™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

• OmniAb Business Combination Approved by APAC Shareholders

  10/24/2022

  Ligand Pharmaceuticals Incorporated announced the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc., was approved by APAC shareholders in a vote held this morning, with 96% of the shares represented in person, virtually or by proxy voting in favor of the combination.

• Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022

  10/3/2022

  Ligand Pharmaceuticals Incorporated announced that on October 3, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 10,770 shares of its common stock to two non-executive employees in connection with their commencement of employment under the Ligand Pharmaceuticals Incorporated 2022 Employee Inducement Plan.

• Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

  10/3/2022

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effect the separation of Ligand and OmniAb into two independent, publicly traded companies.

• Ligand Reports Second Quarter 2022 Financial Results

  8/8/2022

  Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Ligand Pharmaceuticals Incorporated today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates.

• Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Ligand Pharmaceuticals Incorporated announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units and 4,000 performance stock units to six non-executive employees.

• Ligand to Report Second Quarter Financial Results on August 8, 2022

  7/22/2022

  Ligand Pharmaceuticals Incorporated will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.